Survival status and predictors of outcome in patients with brain tumors undergoing surgery at Black Lion Specialized Hospital, Addis Ababa, Ethiopia: A Retrospective Cohort Study

Imagine the human body as a bustling, high-tech city. Most of the time, the construction crews (cells) follow the blueprints perfectly, building and repairing neighborhoods without issue. But sometimes, a construction crew gets a glitchy blueprint and starts building a chaotic, unauthorized structure that grows too fast and blocks the streets. In the brain, this unauthorized structure is called a brain tumor. Because the brain is the city's central command center, these tumors can cause traffic jams (seizures), power outages (neurological deficits), or even shut down the whole city.

Doctors often try to fix this by sending in a specialized demolition team (surgeons) to remove the structure. But just like in a real city, the outcome depends on many things: Is the building made of flimsy, dangerous materials (malignant) or sturdy, harmless ones (benign)? How big is the mess? How old is the city's infrastructure? And how well did the demolition team work? This paper is like a detective story where researchers look back at the records of a specific city's demolition crew to see who survived the longest after the surgery and what factors made the difference between a happy ending and a tragic one.

---

The Story of the Brain City Demolition Crew

Researchers at Black Lion Specialized Hospital in Addis Ababa, Ethiopia, decided to play detective. They looked back at the medical records of 374 adult patients who had brain tumor surgery between January 2020 and December 2022, following them until the end of 2024. Their goal was simple: figure out how long these patients lived after their surgery and, more importantly, what clues predicted who would do well and who would struggle.

Think of the patients as a group of travelers starting a long journey. The researchers wanted to know: How far can they go before the journey ends? And which travelers are likely to get stuck in traffic or run out of gas?

The Big Numbers: How Long Did They Last?

The study found that, on average, the patients survived for 41 months after their surgery. That's a little over three years. If you look at the journey in chunks, about 89% of the travelers were still on the road one year later. By the two-year mark, that number dropped to 57.5%, and by four years, only 48.6% were still traveling.

The Clues That Predicted the Journey's End

The researchers used a special statistical tool (a "survival map") to see which factors were the biggest troublemakers. They found that several things significantly increased the risk of the journey ending early:

• The Age Factor: Being older was a big deal. Travelers between the ages of 55 and 65 were 2.32 times more likely to face an early end compared to those under 35. It's like trying to navigate a complex city with a car that has more miles on it; the older engine just has a harder time handling the stress.
• The "Bad" Building Materials (Malignant Tumors): This was a major predictor. If the tumor was "malignant" (meaning it was aggressive and dangerous), the risk of death more than doubled (2.26 times higher) compared to "benign" (harmless) tumors.
• Specific Types of Trouble: Some specific types of tumors were like particularly stubborn weeds.
  • Glioblastoma (a very aggressive type) made the risk of death 4.14 times higher.
  • Medulloblastoma made it 3.99 times higher.
  • Malignant Ependymoma and Malignant Astrocytoma were also very dangerous, increasing the risk by 4.38 times and 3.68 times, respectively.
  • Crucially, not all "benign" tumors were harmless. Even some tumors classified as benign, such as Schwannoma and "Other benign neoplasms," surprisingly increased the risk of death by about 3 times (specifically 2.93 and 3.61 times higher, respectively). This shows that even "non-cancerous" labels don't always guarantee a safe journey if the tumor is in a tricky spot or behaves aggressively.
• The "Grade" of the Mess: Doctors grade tumors from I to IV, like a difficulty rating in a video game.
  • Grade II tumors made the risk 3.19 times higher.
  • Grade III tumors made it 5.27 times higher.
  • Grade IV (the hardest level) made the risk 6.15 times higher compared to the easiest Grade I tumors.
• Pre-existing Traffic Jams (Neurological Deficits): Patients who already had trouble with their nerves or muscles before surgery (like weakness or vision problems) had a 1.39 times higher risk of not surviving as long. It's like starting a race with a broken leg; the journey is just harder from the start.

What Didn't Matter as Much?

Interestingly, the study found that some things people might guess are important didn't show up as strong predictors in this specific group. For example, whether the patient lived in the city or the countryside, or their sex (male vs. female), didn't significantly change the survival odds once the other factors were taken into account. Also, while removing the whole tumor (total resection) seemed helpful, the data didn't prove it was a guaranteed winner compared to partial removal in this specific analysis, though it was still a positive factor.

The Limits of the Detective Work

The researchers were honest about the holes in their map. Because they were looking at old paper records, some important details were missing. They couldn't check for specific genetic "glitches" in the tumor cells (like IDH mutations) or measure exactly how strong the patients were before surgery using a standard scale (Karnofsky Performance Scale). Also, since all the patients came from just one big hospital in Ethiopia, the results might look different in other hospitals or other countries where the medical tools and treatments are different.

The Takeaway

This study paints a clear picture for doctors and families in Ethiopia: while surgery is a powerful tool, the outcome depends heavily on the type of tumor, how aggressive it is, the patient's age, and their health before the operation. The "bad" tumors, specific types of "benign" tumors that act up, and older age are the heavyweights that make survival harder. The researchers suggest that by spotting these high-risk groups early, doctors can tailor their plans to give these patients the best possible chance to keep their journey going. It's not a magic cure, but it's a vital map for navigating the difficult road of brain tumor treatment.